| Literature DB >> 17665996 |
Andrea Fabbri1, Elisa Giannetta, Andrea Lenzi, Andrea M Isidori.
Abstract
There is still considerable controversy concerning the issue of testosterone replacement therapy. This is because testosterone replacement therapy is not a 'risk-free' treatment and a randomized controlled trial to evaluate safety of prolonged testosterone replacement therapy is not available, nor is it likely to be in the near future. However, recent testosterone delivery systems, such as the 1% gel (Testogel, Androgel and Testim), have proven to have a good physiologic profile, allowing constant monitoring of the possible complications and prompt discontinuation in the event of adverse effects. The aim of this paper is to provide a comprehensive review of the available testosterone preparations to treat male hypogonadism, with special interest in the treatment of ageing men and late-onset hypogonadism. In addition, the experimental and clinical data on the effect of testosterone on sexual function domains is reviewed along with the indication for the combination therapy of androgens with pro-erectile drugs, for example, type 5 phosphodiesterase inhibitors.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17665996 DOI: 10.1517/14712598.7.7.1093
Source DB: PubMed Journal: Expert Opin Biol Ther ISSN: 1471-2598 Impact factor: 4.388